Datasetspublic full text
ClinicalTrials.gov
clinicaltrials · Datasets · License: Public Domain
138,442Documents
1,450Full text
2026-09-19Last indexed
Recent documents from this source
- Study on Booster Immunization With Varicella Vaccine at Different Intervals#314398
- A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds#314397
- Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.#314396
- Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer#314395
- A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals#314394
- A Study to Evaluate the Safety of FluMist in Healthy Children and Healthy Adults#314393
- Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2#314392
- Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors#314391
- Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent)#314390
- Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults#314389
- Vaccine Therapy in Treating Patients With Multiple Myeloma#314388
- Safety, Tolerability and Immunogenicity Study of 2 Dose Levels of Trimeric Glycoprotein140 (gp140) in Healthy Adult Volunteers#314387
- A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1#314386
- Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age#314385
- A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age#314384
- Study to Monitor the Safety and Reactogenicity of Fluarix™ in Korean Subjects Aged > 6 Months of Age.#314383
- Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine#314382
- Observation on the Immune Persistence of People Aged 10-60 Years Old Immunized With Five Doses of Rabies Vaccine#314381
- Efficacy Trial of a Commercial EV71 Vaccine#314380
- French Travelers' Knowledge of Risk of Acquiring ESBL-PE#314379
Source record · clinicaltrials · Datasets · License: Public Domain
Conceptio Open Knowledge Archive — counts are materialised per sync from the index (real full-text coverage, never license entitlement).